EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors ; volume:20 ; number:1 ; day:28 ; month:4 ; year:2020 ; pages:1-13 ; date:12.2020
BMC cancer ; 20, Heft 1 (28.4.2020), 1-13, 12.2020
- Urheber
-
Chiang, Anne C.
Fernandes, Ancilla W.
Pavilack, Melissa
Wu, Jennifer W.
Laliberté, François
Duh, Mei Sheng
Chehab, Nabil
Subramanian, Janakiraman
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-020-06826-0
- URN
-
urn:nbn:de:101:1-2020070823514399847886
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chiang, Anne C.
- Fernandes, Ancilla W.
- Pavilack, Melissa
- Wu, Jennifer W.
- Laliberté, François
- Duh, Mei Sheng
- Chehab, Nabil
- Subramanian, Janakiraman
- SpringerLink (Online service)
Ähnliche Objekte (12)
Second-generation inhibitors of Bruton tyrosine kinase
Neue Inhibitoren der Epidermal Growth Factor related Tyrosine Phosphokinase (EGFrTK), CARN 79079-06-4
Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors
Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005)
Is Turkey Progressing?
Veränderung des Epidermal Growth Factor Receptors (EGFR) bei Sarkomen
Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations
![Is Volapük progressing? : [Kopftitel]](https://iiif.deutsche-digitale-bibliothek.de/image/2/8be7e498-73fb-459e-b546-97f7ae30c2ce/full/!306,450/0/default.jpg)
Is Volapük progressing? : [Kopftitel]
Second-generation inhibitors of Bruton tyrosine kinase
Neue Inhibitoren der Epidermal Growth Factor related Tyrosine Phosphokinase (EGFrTK), CARN 79079-06-4
Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors
Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005)
Is Turkey Progressing?
Veränderung des Epidermal Growth Factor Receptors (EGFR) bei Sarkomen
Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations
Is Volapük progressing? : [Kopftitel]
Second-generation inhibitors of Bruton tyrosine kinase
Neue Inhibitoren der Epidermal Growth Factor related Tyrosine Phosphokinase (EGFrTK), CARN 79079-06-4
Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors
Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005)
Is Turkey Progressing?
Veränderung des Epidermal Growth Factor Receptors (EGFR) bei Sarkomen
Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations